SEARCH:   Advanced

Blood, 1 July 2005, Vol. 106, No. 1, pp. 167-174. Prepublished online as a Blood First Edition Paper on March 10, 2005; DOI 10.1182/blood-2004-12-4931. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-12-4931v1 106/1/167    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jungbluth, A. A. Articles by Cho, H. J. Search for Related Content PubMed PubMed Citation Articles by Jungbluth, A. A. Articles by Cho, H. J. Related Collections Immunobiology Neoplasia Immunotherapy Free Research Articles Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation Achim A. Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J. Old, and Hearn Jay Cho From the New York Branch, Ludwig Institute for Cancer Research, New York, NY; Department of Pathology, Weill Medical College of Cornell University, New York, NY; Division of Hematology/Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY; Graduate Program in Immunology and Microbial Pathogenesis, Weill Graduate School of Medical Sciences, New York, NY; and the New York University School of Medicine, New York, NY. Multiple myeloma is a malignancy of plasma cells. Vaccine immunotherapy is among the novel therapeutic strategies under investigation for this disease. To identify myeloma-associated antigens as potential targets for vaccine immunotherapy, we surveyed a comprehensive panel of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma for expression of cancer-testis (CT) antigens. Immunohistochemistry (IHC) demonstrated that 82% of stage-III myeloma specimens expressed the CT antigen CT7 (also known as melanoma antigen C1 [MAGE-C1]) and 70% expressed MAGE-A3/6. Messenger RNA for CT7 and MAGE-A family members was detected in 87% and 100% of stage-III samples, respectively. CT7 protein expression increased with advanced stage of disease. Higher levels of CT7 and MAGE-A3/6 proteins also correlated with elevated plasma-cell proliferation. These results show that CT7 and MAGE-A3/6 are promising myeloma-associated antigens for application in vaccine immunotherapy. Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Should MAGE be the rage in myeloma? Carol Ann Huff and Judith E. Karp Blood 2005 106: 5. [Full Text] [PDF] This article has been cited by other articles: M. Condomines, D. Hose, T. Reme, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, and B. Klein Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma J. Immunol., July 15, 2009; 183(2): 832 - 840. [Abstract] [Full Text] [PDF] D. Atanackovic, T. Luetkens, Y. Hildebrandt, J. Arfsten, K. Bartels, C. Horn, T. Stahl, Y. Cao, A. R. Zander, C. Bokemeyer, et al. Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma Clin. Cancer Res., February 15, 2009; 15(4): 1343 - 1352. [Abstract] [Full Text] [PDF] O. C. Goodyear, G. Pratt, A. McLarnon, M. Cook, K. Piper, and P. Moss Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Blood, October 15, 2008; 112(8): 3362 - 3372. [Abstract] [Full Text] [PDF] B. Yang, S. M. O'Herrin, J. Wu, S. Reagan-Shaw, Y. Ma, K. M.R. Bhat, C. Gravekamp, V. Setaluri, N. Peters, F. M. Hoffmann, et al. MAGE-A, mMage-b, and MAGE-C Proteins Form Complexes with KAP1 and Suppress p53-Dependent Apoptosis in MAGE-Positive Cell Lines Cancer Res., October 15, 2007; 67(20): 9954 - 9962. [Abstract] [Full Text] [PDF] J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood, July 1, 2007; 110(1): 296 - 304. [Abstract] [Full Text] [PDF] M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al. Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis J. Immunol., March 1, 2007; 178(5): 3307 - 3315. [Abstract] [Full Text] [PDF] N. Gonzalez-Paz, W. J. Chng, R. F. McClure, E. Blood, M. M. Oken, B. V. Ness, C. D. James, P. J. Kurtin, K. Henderson, G. J. Ahmann, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications Blood, February 1, 2007; 109(3): 1228 - 1232. [Abstract] [Full Text] [PDF] D. Atanackovic, J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation Blood, February 1, 2007; 109(3): 1103 - 1112. [Abstract] [Full Text] [PDF] S. S. Sahota, C. M. Goonewardena, C. D. O. Cooper, A. P. Liggins, K. Ait-Tahar, N. Zojer, F. K. Stevenson, A. H. Banham, and K. Pulford PASD1 is a potential multiple myeloma-associated antigen. Blood, December 15, 2006; 108(12): 3953 - 3955. [Full Text] [PDF] V. C. d. C. Andrade, G. W. B. Colleoni, A. L. Vettore, R. S. Felix, M. S.S. Almeida, F. Carvallho, M. Yamamoto, and M. A. Zago Frequent Expression of Cancer/Testis Antigens CT7 and LAGE-1 in Advanced Stage Multiple Myeloma: Are They Possible Targets for Immunotherapy?. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 5034 - 5034. [Abstract] [PDF] H.-J. Heidebrecht, A. Claviez, M. L. Kruse, M. Pollmann, F. Buck, S. Harder, M. Tiemann, W. Dorffel, and R. Parwaresch Characterization and Expression of CT45 in Hodgkin's Lymphoma. Clin. Cancer Res., August 15, 2006; 12(16): 4804 - 4811. [Abstract] [Full Text] [PDF] M. Monte, M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents PNAS, July 25, 2006; 103(30): 11160 - 11165. [Abstract] [Full Text] [PDF] O. Goodyear, K. Piper, N. Khan, J. Starczynski, P. Mahendra, G. Pratt, and P. Moss CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden Blood, December 15, 2005; 106(13): 4217 - 4224. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020